165 related articles for article (PubMed ID: 18045851)
1. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Tu X; Chen X; Xie Y; Shi S; Wang J; Chen Y; Li J
J Am Soc Nephrol; 2008 Jan; 19(1):77-83. PubMed ID: 18045851
[TBL] [Abstract][Full Text] [Related]
2. Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.
Li P; Ma LL; Xie RJ; Xie YS; Wei RB; Yin M; Wang JZ; Chen XM
Acta Pharmacol Sin; 2012 May; 33(5):644-51. PubMed ID: 22555371
[TBL] [Abstract][Full Text] [Related]
3. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
Li S; Cao B; Feng QH; Li XZ
Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
[TBL] [Abstract][Full Text] [Related]
4. Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.
Zhao G; Zhao H; Tu L; Xu X; Zheng C; Jiang M; Wang P; Wang D
J Huazhong Univ Sci Technolog Med Sci; 2010 Feb; 30(1):48-54. PubMed ID: 20155455
[TBL] [Abstract][Full Text] [Related]
5. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G
J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial.
DeSilvey DL
Am J Geriatr Cardiol; 2006; 15(5):326-7. PubMed ID: 16957455
[No Abstract] [Full Text] [Related]
7. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
[TBL] [Abstract][Full Text] [Related]
8. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
[TBL] [Abstract][Full Text] [Related]
9. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
De Rosa ML; de Cristofaro A; Rossi M; Baiano A; Cardace P; Albanese L; Vigorito C
J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
[TBL] [Abstract][Full Text] [Related]
10. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG
Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
[TBL] [Abstract][Full Text] [Related]
11. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
; Connolly S; Pogue J; Hart R; Pfeffer M; Hohnloser S; Chrolavicius S; Pfeffer M; Hohnloser S; Yusuf S
Lancet; 2006 Jun; 367(9526):1903-12. PubMed ID: 16765759
[TBL] [Abstract][Full Text] [Related]
12. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
[TBL] [Abstract][Full Text] [Related]
13. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
14. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
Gartenmann AC; Fossali E; von Vigier RO; Simonetti GD; Schmidtko J; Edefonti A; Bianchetti MG
Kidney Int; 2003 Oct; 64(4):1450-4. PubMed ID: 12969165
[TBL] [Abstract][Full Text] [Related]
15. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
16. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
[TBL] [Abstract][Full Text] [Related]
17. [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Meinertz T
Internist (Berl); 2007 Aug; 48(8):874-5. PubMed ID: 17628764
[No Abstract] [Full Text] [Related]
18. Ticlopidine prevents renal disease progression in rats with reduced renal mass.
Zoja C; Perico N; Bergamelli A; Pasini M; Morigi M; Dadan J; Belloni A; Bertani T; Remuzzi G
Kidney Int; 1990 Mar; 37(3):934-42. PubMed ID: 2313981
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
Takai S; Jin D; Sakonjo H; Miyazaki M
Hypertens Res; 2010 Sep; 33(9):953-9. PubMed ID: 20520612
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats.
Liu BC; Chen Q; Luo DD; Sun J; Phillips AO; Ruan XZ; Liu NF
Acta Pharmacol Sin; 2003 Jan; 24(1):67-73. PubMed ID: 12511232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
